+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 12Years +
All Genders
ID07905911

Study of Maximum Lysis by Thromboelastography to Assess Severity in Acute Allergic Reactions

Led by Mayo Clinic · Updated on 2026-10-30

250

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to better understand the biological mechanisms behind allergic reactions, including anaphylaxis, by studying real-time physiologic markers. The goal is to combine these markers with future molecular findings to develop better ways to classify allergic reaction types and improve risk prediction. The study is observational and focuses on acute allergic reactions. Participants will undergo blood testing using thromboelastography during their acute allergic reaction presentation to the emergency department. This test measures maximum lysis, a marker of systemic severity in allergic reactions. The study follows patients for up to four years to assess outcomes such as hospital admission and intensive care unit use. Throughout the study, participants will have thromboelastography performed during their acute episode. Researchers will collect data on the severity of allergic reactions and follow long-term outcomes. The main measurement is maximum lysis by allergic reaction severity at baseline, with secondary outcomes including hospital and intensive care utilization over four years. The study runs from October 2026 through September 2031.

CONDITIONS

Brief Title

Maximum Lysis on Thromboelastography as a Marker of Systemic Severity in Acute Allergic Reactions

Research Team

S

Study Coordinator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here